Intervillous Thrombus in Placental Pathology: Understanding Clinical Associations and Implications

Understanding Clinical Associations and Implications

Pathology · Seminar week 25 · released August 20, 2026 · includes a discussion video

Recent studies highlight intervillous thrombus (IVT) as being independently associated with placental infarcts, single umbilical artery, and fetal inflammatory response,…

Learning Objectives

• Define intervillous thrombus using precise gross and histologic criteria.
• Distinguish intervillous thrombus from placental infarction, fetal vascular malperfusion, hematoma, and extensive perivillous fibrin deposition.
• Appraise evidence linking intervillous thrombus with infarction, single umbilical artery, and fetal inflammatory response.
• Compare maternal-thrombosis, fetal-hemorrhage, and flow-disturbance models of pathogenesis.
• Design a standardized, bias-aware placental pathology database.
• Translate placental findings into proportionate obstetric, neonatal, and recurrence counseling.
• Avoid unsupported thrombophilia testing, anticoagulation, or causal attribution after an isolated intervillous thrombus.

Definition and Historical Context of Intervillous Thrombus

%%FIG0%% Duration: 10 minutes

An intervillous thrombus, or IVT, is a discrete clot within the placental intervillous space—the maternal-blood compartment surrounding the fetal chorionic villi. It is not simply “fibrin deposition.” Grossly, a recent IVT is usually a circumscribed, red-brown, soft intraparenchymal lesion; with organization and erythrocyte degeneration, it becomes firmer and paler. Histologically, a classic lesion contains alternating layers of erythrocytes, fibrin, and platelets, sometimes forming lines of Zahn. Villi are commonly compressed, displaced to the periphery, or entrapped in the clot. Remote lesions may become predominantly eosinophilic and difficult to separate grossly from an infarct or fibrin plaque.

Teaching Point: Routine hematoxylin-and-eosin morphology establishes that a lesion is a thrombus, but it cannot reliably establish whether the erythrocytes are maternal or fetal. The intervillous space normally contains maternal blood, yet entrapped fetal cells, villi, or trophoblast can complicate ancillary testing.

The historical debate concerns whether IVT represents primary thrombosis of maternal blood or clotting initiated by fetal hemorrhage through a damaged villous surface. Wentworth’s 1964 work established IVT as a recognizable placental lesion but left its clinical importance unresolved. Kaplan and colleagues later identified fetal hemoglobin-containing erythrocytes in 85% of assessable IVTs, shifting opinion toward a fetal-hemorrhage model (PMID: 6176524). A 1986 blood-group study, however, estimated that approximately 88% of thrombus erythrocytes were maternal and 12% fetal (PMID: 2429464). These observations are compatible with a small fetal bleed seeding a much larger maternal clot.

Modern testing has further revised the model. In a ten-case study using short-tandem-repeat genotyping, sex-chromosome fluorescence in situ hybridization, and immunohistochemistry for fetal alpha-fetoprotein versus maternal immunoglobulin M, nine IVTs were predominantly or entirely maternal and one was mixed. The same study found no association between IVT and clinically detectable fetomaternal hemorrhage (PMID: 34546332). Its direct-origin series was small and drawn from pregnancies with SARS-CoV-2 exposure, but it provides the best current evidence that most of the clot mass is maternal.

Nuance: “Kline hemorrhage” is an older designation for intervillous hemorrhage interpreted as fetal bleeding. It should not be used as a synonym for every IVT. Conversely, finding a predominantly maternal clot does not exclude a microscopic fetal vascular breach as the initiating event.

IVT frequency varies dramatically with ascertainment. A population-based term study found IVT in 6% of 1,038 placentas, while systematic examination of 944 uncomplicated term placentas found IVT in 10.3% (PMIDs: 15255032, 30044764). A recent pathology-selected cohort reported 20.6%. Differences in submission criteria, grossing, sampling, diagnostic thresholds, and case mix make these figures noninterchangeable.

Framework: The differential is anatomical. A villous infarct is centered on ischemic coagulative necrosis of chorionic villi. Fetal vascular malperfusion contains thrombi within fetal vessels and may produce downstream avascular villi. A retroplacental hematoma lies behind and dissects or compresses the basal plate; a subchorionic thrombus lies beneath the chorionic plate. Focal perivillous fibrin coats or bridges villi rather than forming a laminated, villus-displacing clot. Massive perivillous fibrin deposition is a diffuse encasing process with substantially different outcome and recurrence implications. Hemorrhage surrounded by infarction should be reported as an infarction hematoma.

MUST ACT: The pathology report should state the number, greatest dimensions, location, estimated percentage of parenchyma involved, degree of organization, and adjacent villous injury. It should separately assess infarction, maternal and fetal vascular malperfusion, abruption, extensive perivillous fibrin, cord abnormalities, and inflammation. A small isolated IVT should not be transformed into a diagnosis of placental insufficiency, fetomaternal hemorrhage, or systemic thrombophilia.

Audience Poll: Which feature most strongly supports IVT rather than infarction: a pale gross appearance, a laminated clot-rich center, surrounding compressed villi, or association with hypertension?

Clinical Associations: Placental Infarct, Single Umbilical Artery, and Fetal Inflammatory Response

%%FIG1%% Duration: 15 minutes

The most directly relevant contemporary evidence comes from a database analysis of 3,119 pathology-submitted placentas linked with maternal and birth data. IVT was identified in 644 placentas, or 20.6%. On initial analysis it was associated with advanced maternal age, preeclampsia, placental infarction, mural arterial hypertrophy, abruption, and velamentous cord insertion. After regression, associations persisted with placental infarction, a two-vessel cord or single umbilical artery, and fetal inflammatory response, defined as acute funisitis or fetal vasculitis (PMID: 41307115).

MUST ACT: “Independently associated” means that an association remained in the investigators’ adjusted model. It does not establish temporal order, causality, treatment benefit, or that IVT caused fetal compromise. The cohort consisted of selected placentas, not a population screening sample, and the published abstract does not provide effect sizes or confidence intervals.

The infarction association is biologically plausible but requires disciplined interpretation. Infarction is a lesion of interrupted maternal perfusion and belongs to the maternal vascular malperfusion spectrum when accompanied by findings such as a small placenta, distal villous hypoplasia, accelerated villous maturation, or decidual arteriopathy. An IVT may coexist with an infarct because regional flow disturbance promotes both lesions, because the clot compresses adjacent villi, or because both reflect a third process such as abruption or abnormal placentation. IVT itself is not an Amsterdam-defining lesion of maternal vascular malperfusion.

The older Auckland Birthweight Collaborative Study illustrates why co-occurrence and clinical prediction must be separated. Among 509 small-for-gestational-age and 529 appropriate-for-gestational-age term births, IVT occurred in 64 placentas and co-occurred with marginal infarcts and intervillous fibrin plaques. Unlike infarction, however, IVT was not independently associated with small-for-gestational-age birth or pregnancy-induced hypertension (PMID: 15255032). Differences from the recent report may reflect population selection, lesion definitions, statistical power, and changes in obstetric practice.

Nuance: The association with single umbilical artery is novel. A true single umbilical artery may arise from primary agenesis, persistence of the original embryonic artery, or secondary atrophy. An acquired umbilical artery thrombosis can occasionally produce a “pseudo-SUA” appearance, so antenatal and pathologic findings should be reconciled. An isolated SUA frequently has a favorable outcome, whereas a non-isolated SUA warrants careful evaluation for structural and genetic abnormalities. The remaining artery often enlarges and compensates; therefore, SUA does not automatically imply inadequate fetal placental perfusion.

The proposed connection is hemodynamic: altered fetal-side flow could increase regional shear, redistribute villous perfusion, or predispose to microscopic villous-capillary injury. Yet IVT occupies a predominantly maternal compartment. A causal pathway would therefore need to cross the villous barrier—for example, through trophoblast injury, a small fetal leak that initiates maternal coagulation, or a shared placental developmental abnormality. Residual confounding is equally possible.

Fetal inflammatory response is also a specific histologic diagnosis, not a generic statement that the fetus was “inflamed.” Under Amsterdam criteria, stage 1 includes chorionic vasculitis or umbilical phlebitis; stage 2 involves the umbilical vein and at least one artery; stage 3 is necrotizing funisitis. Neutrophils originate from the fetal circulation and most often respond to chemotactic signals generated during ascending intra-amniotic inflammation or infection. FIR may accompany fetal systemic inflammation, particularly in preterm birth, but its association with IVT does not show that the thrombus caused infection or inflammation.

Framework: Interpret the triad by compartments: infarction points principally toward maternal perfusion; SUA modifies the fetal conduit; FIR reflects fetal inflammatory-cell trafficking. IVT may be a common downstream marker at their interface rather than the primary disease.

Decision Point: When IVT, infarction, SUA, and FIR coexist, ask which lesion has sufficient severity and temporal plausibility to explain the clinical outcome. A focal IVT should not eclipse severe chorioamnionitis, extensive infarction, abnormal Dopplers, abruption, or true fetal growth restriction.

Audience Poll: Does the new adjusted association with SUA make fetal hemorrhage the most likely cause of all IVTs, or does it primarily generate a testable mechanistic hypothesis?

The Pathophysiologic Mechanisms of IVT

%%FIG2%% Duration: 15 minutes

Maternal blood enters the intervillous space through remodeled spiral arteries, circulates around the chorionic villi, and exits through uterine veins. Fetal blood remains within the villous capillary tree, arriving through the umbilical arteries and returning through the umbilical vein. Exchange occurs across trophoblast, villous stroma, and fetal capillary endothelium without normal bulk mixing of the two circulations. An IVT therefore forms in a maternal-blood space adjacent to, but outside, the fetal vasculature.

Framework: Three mechanisms are plausible and need not be mutually exclusive. First, a microscopic fetal-capillary or trophoblast breach may release fetal blood into the intervillous space, initiating coagulation of surrounding maternal blood. Second, maternal blood may thrombose locally because of stasis, altered inflow, pregnancy-associated hypercoagulability, or trophoblast injury. Third, another lesion—such as a subchorionic cyst, intraplacental hemorrhage, infarct, or inflammatory focus—may provide a procoagulant nidus.

The first model reconciles historical detection of fetal hemoglobin with modern evidence that the clot is predominantly maternal. A small amount of fetal blood could be biologically important without constituting most of the lesion. Nevertheless, the modern origin study found IVT in 7.2% of cases with flow-cytometry-confirmed fetomaternal hemorrhage and 10% without hemorrhage; neither hemorrhage volume nor IVT size showed a significant association (PMID: 34546332). Clinically important fetomaternal hemorrhage is therefore not a general explanation for IVT.

The maternal-thrombosis model adapts Virchow’s triad. Pregnancy supplies systemic hypercoagulability; altered maternal inflow or peripheral stasis supplies disturbed flow; and trophoblast denudation or activation substitutes for conventional endothelial injury because the intervillous surface is trophoblast-lined. Local fibrin deposition normally repairs small areas of trophoblast loss, but a true IVT is a larger, laminated coagulative event. Diabetes, preeclampsia, and abruption can create prothrombotic or flow-disturbed environments, although their observational associations do not establish a lesion-specific mechanism.

Nuance: Maternal systemic hypercoagulability alone is insufficient as an explanation. IVT is common in uncomplicated placentas, and neither inherited thrombophilia nor antiphospholipid syndrome has a unique IVT signature. Conversely, fetal vascular malperfusion must not be diagnosed merely because an IVT is called a “thrombus.” Fetal vascular malperfusion requires fetal-vessel or downstream villous findings such as chorionic or stem-vessel thrombosis, villous stromal-vascular karyorrhexis, or avascular villi.

The SUA and FIR associations add a cross-compartment hypothesis. SUA may alter fetal vascular resistance or regional distribution, while inflammation may injure fetal endothelium and trophoblast. Either could increase the probability of a small barrier breach or change local maternal washout. However, FIR may simply identify pregnancies with prolonged labor, membrane rupture, infection, or preterm delivery—variables that also influence placental examination and lesion detection. Postpartum histology cannot determine which event occurred first.

How much does an IVT impair function? The answer depends on burden, location, placental reserve, and adjacent damage. A small lesion removes little exchange surface and is often incidental. Multiple or large lesions can displace perfused maternal blood, compress villi, and produce secondary ischemic injury. A strategically located lesion in a small or already infarcted placenta may matter more than a larger lesion in an otherwise healthy term placenta. Evidence does not support assuming that every IVT caused chronic fetal hypoxia or “brain-sparing.” Those conclusions require corroboration from growth trajectory, amniotic fluid, fetal surveillance, Doppler findings, intrapartum tracing, cord gases, and neonatal condition.

Antenatal recognition is uncommon. Large IVTs may appear as echogenic or complex cystic intraplacental lesions with little internal flow, but ultrasound correlation is imperfect. Differential considerations include a placental lake with low-velocity swirling flow, infarction, subchorionic hematoma, chorangioma, massive subchorionic thrombohematoma, and placenta-accreta-spectrum lacunae. A selected imaging series found that only about half of sonographic echogenic cystic lesions had a gross correlate, although IVT was common among confirmed lesions (PMID: 21035847).

MUST ACT: A suspicious antenatal placental lesion should trigger characterization, not empiric “clot treatment.” Document size and location, apply color Doppler, reassess fetal growth and fluid, obtain umbilical-artery Doppler when indicated, and evaluate the mother for hypertension or abruption symptoms.

Decision Point: Do not order Kleihauer–Betke testing, flow cytometry, or additional Rh immune globulin because pathology later reports an IVT. Investigate fetomaternal hemorrhage when the clinical phenotype supports it—reduced fetal movement, sinusoidal tracing, unexplained fetal or neonatal anemia, hydrops, shock, trauma, abruption, or stillbirth.

Audience Poll: Which model best explains a predominantly maternal IVT containing scattered fetal erythrocytes: primary maternal thrombosis, microscopic fetal hemorrhage with maternal amplification, or a mixed mechanism?

Research Methodologies in Placental Pathology: Building a Placentas Database

%%FIG3%% Duration: 10 minutes

A useful placental database begins with a defined question. Prevalence, etiologic association, clinical prediction, and treatment selection require different designs. The recent 3,119-placenta IVT report is an observational database analysis—not a randomized trial—and should not be relabeled the “PLACENTAL trial.” No recognized IVT treatment trial by that name supports clinical recommendations. Its value lies in hypothesis generation and linkage of placental, maternal, and fetal variables (PMID: 41307115).

Framework: Build the hierarchy as mother → pregnancy → delivery → placenta → placental territory → block → slide or whole-slide image → annotated lesion. Repeated pregnancies require maternal clustering. Twins require chorionicity, infant-specific cord linkage, mapped placental territories, and rules for shared lesions. A flat spreadsheet with one row per placenta cannot reliably represent these relationships.

Standardization starts at the gross bench. The Amsterdam Placental Workshop Group recommends recording trimmed placental weight and whether the organ was fresh or fixed; disc dimensions and thickness; cord length, diameter, coiling, insertion, and vessel number; membrane appearance and completeness; and basal-plate integrity. Gross lesions should be counted, measured in two dimensions or estimated as a percentage of parenchymal volume, mapped as central, paracentral, or peripheral, photographed, and sampled with adjacent normal tissue (PMID: 27223167).

Minimum Amsterdam sampling uses four cassettes: a membrane roll extending from the rupture edge to the placental margin with marginal parenchyma and two cord cross-sections, plus three full-thickness samples of normal-appearing central parenchyma, including one near the cord insertion. Gross lesions require additional blocks. Because Amsterdam does not provide a dedicated quantitative IVT grade, the database must define one prospectively: gross and microscopic confirmation, number, dimensions, total burden, location, qualitative organization, villous compression or incorporation, and associated infarction or hemorrhage.

MUST ACT: Store IVT separately from infarction, infarction hematoma, fetal-vessel thrombosis, retroplacental hematoma, subchorionic thrombus, perivillous fibrin, and massive perivillous fibrin deposition. Binary “present/absent” coding discards the burden and context most likely to determine clinical relevance.

Clinical linkage should include maternal age, parity, body mass index, smoking and substance exposure, diabetes phenotype, hypertensive diagnosis and timing, autoimmune disease, APS, prior thrombosis, medications, infection, membrane-rupture duration, labor, fever, antibiotics, gestational age, and delivery indication. Fetal variables should include sex, anomalies, genetic results, longitudinal biometry, fluid, Dopplers, tracing interpretation, birthweight percentile, cord gases, resuscitation, early-onset sepsis evaluation, hematocrit, NICU diagnoses, and longitudinal neurodevelopment. Each field needs a versioned data dictionary distinguishing “absent,” “unknown,” and “not assessed.”

Selection bias is a central threat. Placentas are commonly submitted because an adverse outcome, maternal disease, or fetal abnormality has already occurred. Comparing lesions only within submitted specimens can overestimate prevalence, distort associations, and create collider bias. A credible study records the denominator of all deliveries, the indication for submission, specimens not examined, and differences between examined and unexamined births. Universal prospective collection, random sampling, or inverse-probability-of-selection methods are preferable to an unexplained convenience sample.

Nuance: Observer effects matter as much as statistical effects. Use a written atlas, pathologist training, blinded duplicate review, adjudication, and periodic interobserver-agreement audits. Whole-slide-image models must split data by patient rather than slide, because slides from the same placenta in training and validation sets create serious leakage. Automated segmentation should quantify lesion burden but remain subject to pathologist review.

Analysis should be prespecified. A directed acyclic graph can clarify whether gestational age, labor, infection, growth restriction, and delivery mode are confounders, mediators, or consequences. Repeated pregnancies, twins, hospitals, and readers require mixed models or generalized estimating equations. Report adjusted effect sizes with 95% confidence intervals, not only P values. Address missing data, multiple comparisons, calibration, temporal validation, and external replication. A regression coefficient cannot repair an invalid phenotype or biased sampling frame.

Biobanking adds mechanistic depth. Archive formalin-fixed paraffin-embedded blocks and, when feasible, prospectively collect frozen thrombus core, organizing rim, adjacent villi, distant normal parenchyma, maternal blood, cord blood, and placental-bed tissue. Record delivery-to-fixation or freezing time, labor exposure, fetal sex, gestational age, and batch. Spatially matched sampling is essential because placental gene and protein expression varies across the disc.

Decision Point: Before querying an association, decide what observation would change practice. If the database cannot distinguish a single 4-mm IVT from multifocal lesions involving 20% of a small placenta, it cannot produce clinically actionable risk estimates.

Audience Poll: Which design change would most improve causal inference: a larger selected cohort, universal placental sampling, more covariates in regression, or blinded standardized lesion quantification?

Implications for Obstetrics and Neonatal Outcomes

%%FIG4%% Duration: 10 minutes

Most IVTs are diagnosed after delivery. The pathologic finding therefore usually explains or contextualizes an outcome rather than directing the completed pregnancy. A small isolated IVT is common and often incidental. Clinical weight increases with multiplicity, large parenchymal burden, adjacent infarction, a small placenta, abruption, extensive fibrin, fetal vascular malperfusion, cord disease, or inflammatory lesions.

MUST ACT: Treat the clinical phenotype, not the word “thrombus.” Do not initiate aspirin, unfractionated heparin, or low-molecular-weight heparin solely because a previous placenta contained a focal IVT. There is no IVT-specific drug trial, delivery threshold, or validated recurrence-prevention regimen.

If SUA is identified antenatally, confirm whether it is isolated through a detailed anatomic survey, including careful cardiac and renal assessment. Additional genetic evaluation is driven by coexisting anomalies or screening results, not isolated SUA alone. A third-trimester growth assessment is recommended, and weekly antenatal surveillance may be considered from 36 weeks (PMIDs: 34171388, 34011892). Earlier or more frequent surveillance is determined by growth, Dopplers, maternal disease, fetal movement, and other abnormalities—not by a presumed antenatal IVT.

When fetal growth restriction is present, follow a defined FGR protocol. SMFM defines FGR as estimated fetal weight or abdominal circumference below the tenth percentile. Umbilical-artery Doppler is generally repeated every one to two weeks after diagnosis, weekly when estimated fetal weight is below the third percentile or diastolic resistance is increased, and two to three times weekly with absent end-diastolic velocity. Cardiotocographic surveillance is at least weekly after viability in stable FGR and intensified with absent or reversed flow or comorbidity. Suggested delivery timing is 38–39 weeks for estimated fetal weight from the third to tenth percentile with normal Doppler; 37 weeks for estimated fetal weight below the third percentile or decreased diastolic flow; 33–34 weeks with absent end-diastolic velocity; and 30–32 weeks with reversed flow, individualized to the full clinical picture (PMID: 32407785).

Decision Point: If delivery is anticipated before 33 6/7 weeks, administer antenatal corticosteroids; they may also be appropriate from 34 0/7 through 36 6/7 weeks when birth within seven days is likely and no previous course was given. Magnesium sulfate is recommended for fetal neuroprotection when delivery before 32 weeks is expected. These interventions respond to prematurity and placental dysfunction, not directly to IVT.

Low-dose aspirin is appropriate when the patient independently meets preeclampsia-risk criteria. In United States guidance, the standard regimen is 81 mg daily beginning between 12 and 28 weeks, optimally before 16 weeks, and continued until delivery (PMID: 29939940). The ASPRE trial used 150 mg nightly from 11–14 weeks through 36 weeks in women classified as high risk by a specific first-trimester algorithm (PMID: 28657417). These are preeclampsia-prevention protocols, not IVT treatments, and dosing should follow the applicable guideline and local formulary.

Confirmed obstetric APS is different. Patients meeting clinical and persistent laboratory criteria are generally treated with low-dose aspirin plus prophylactic heparin; a common prophylactic regimen is enoxaparin 40 mg subcutaneously daily. Patients with thrombotic APS or acute venous thromboembolism generally need therapeutic weight-based LMWH, often enoxaparin 1 mg/kg every 12 hours, with adjustment for renal function, weight, bleeding risk, delivery timing, and neuraxial anesthesia (PMID: 30482767). An isolated IVT does not establish APS and is not an indication for this regimen.

Neonatal care is similarly phenotype-based. A vigorous appropriate-for-gestational-age newborn does not require NICU admission, antibiotics, neuroimaging, coagulation studies, or a complete blood count because of IVT alone. An SGA infant requires glucose, temperature, feeding, and growth surveillance. Pallor, hypotension, hydrops, unexplained metabolic acidosis, or a sinusoidal fetal tracing should prompt evaluation for anemia or fetomaternal hemorrhage. Neurologic depression and significant acidemia require standard hypoxic-ischemic encephalopathy assessment, including timely consideration of therapeutic hypothermia.

FIR should be communicated to neonatology but is not synonymous with culture-proven sepsis. For infants at or beyond 35 weeks, early-onset sepsis decisions should integrate maternal fever or suspected intra-amniotic infection, group B streptococcal status, membrane-rupture duration, intrapartum antibiotics, gestational age, and serial newborn examinations (PMID: 30455342). Pathology often returns after the immediate treatment window; a clinically well infant should not automatically receive delayed antibiotics solely for histologic FIR.

Maternal follow-up should address the actual obstetric syndrome: postpartum blood-pressure surveillance after gestational hypertension or preeclampsia, diabetes follow-up, cardiovascular-risk counseling, and review of abruption or stillbirth evaluation when applicable. Routine inherited-thrombophilia panels after isolated IVT create false positives and rarely change management. APS testing is reserved for qualifying thrombosis or obstetric histories, and positive antibodies must be confirmed according to persistence criteria.

Teaching Point: Recurrence risk for an isolated focal IVT is undefined. Do not borrow the high recurrence estimates of massive perivillous fibrin deposition or chronic histiocytic intervillositis. Future-pregnancy planning should be driven by prior preeclampsia, FGR, abruption, stillbirth, APS, or venous thromboembolism—not by IVT in isolation.

Audience Poll: Which finding would most change next-pregnancy management: a solitary 1-cm IVT, extensive infarction with FGR, confirmed obstetric APS, or isolated term histologic FIR?

Future Directions in Research and Clinical Practice

%%FIG5%% Duration: 10 minutes

The next research step is not simply a larger retrospective count. IVT needs a reproducible phenotype connected to lesion burden, clot composition, antenatal physiology, and meaningful outcomes. A multicenter prospective study should enroll an all-delivery or randomly sampled denominator, apply Amsterdam-standard grossing, quantify every IVT, and link pathology with serial fetal growth, maternal blood pressure, placental imaging, Dopplers, cord gases, neonatal physiology, and subsequent development.

Framework: The central mechanistic questions are separable: What initiates the lesion? Whose blood forms its bulk? Which lesions impair exchange? Which findings merely travel with another disease? Maternal-versus-fetal origin can be tested using paired genotyping, sex-chromosome FISH in informative cases, and IgM-versus-alpha-fetoprotein immunohistochemistry. Core, rim, adjacent-villus, and distant-control sampling can distinguish the mature clot from the initiating tissue reaction.

Digital pathology can improve consistency. Whole-slide algorithms could detect laminated clot, separate IVT from infarction and fibrin, quantify area and spatial distribution, and flag discordance between narrative reports and images. Training must include mimics, multiple institutions, scanners, gestational ages, and demographic groups. Patient-level data splits, external validation, calibration, and pathologist adjudication are mandatory; high slide-level accuracy is clinically meaningless if the same placenta leaks across training and test sets.

Spatial transcriptomics, multiplex immunofluorescence, proteomics, and imaging mass cytometry may reveal whether the organizing rim contains trophoblast stress, complement activation, platelet recruitment, neutrophil signaling, or altered fibrinolysis. Single-cell approaches can characterize trophoblast, Hofbauer-cell, endothelial, and maternal immune states, although dissociation and compartment contamination are major pitfalls. A postpartum molecular signature still cannot establish temporal precedence unless connected to antenatal samples or experimental models.

Nuance: Placental imaging remains investigational for IVT. Advanced ultrasound, three-dimensional power Doppler, placental MRI, diffusion methods, and oxygen-sensitive MRI may characterize perfusion and oxygenation, but none currently provides validated screening or treatment thresholds for microscopic IVT. Imaging studies should predefine pathology correlation, scan-to-delivery interval, lesion registration, and whether an apparent mass represents a lake, hematoma, infarct, thrombus, or tumor.

Experimental systems should reproduce the maternal–fetal interface rather than treating IVT like a conventional deep-vein thrombus. Perfused placental cotyledons, trophoblast-endothelial organoids, microfluidic villous-barrier models, and computational flow simulations could test whether altered maternal washout, SUA-like fetal resistance, inflammatory cytokines, or focal capillary rupture generates a laminated maternal clot. Parallel measurement of tissue factor, thrombin generation, platelets, fibrinolysis, complement, and barrier permeability would distinguish competing mechanisms.

Clinical research should proceed only after risk phenotypes are defined. A treatment trial enrolling anyone with “prior IVT” would combine incidental focal lesions with extensive recurrent placental disease and probably produce an uninterpretable result. Future trials should require a reproducible high-risk phenotype, specify whether the intervention targets preeclampsia, APS, inflammation, or coagulation, and use outcomes such as live birth, severe FGR, stillbirth, gestational age, and neonatal morbidity—not disappearance of a histologic finding alone.

MUST ACT: Research reports should publish the denominator, submission indication, sampling protocol, IVT definition, lesion burden, co-lesions, missingness, effect sizes, and external validation. The current evidence supports contextual reporting and proportionate surveillance; it does not support IVT-specific anticoagulation.

Translation also requires better communication. Pathology reports should distinguish “focal IVT of uncertain clinical significance” from extensive lesions with loss of functional parenchyma. Unexpected findings that could affect current maternal or neonatal care should be communicated promptly, but IVT alone is not a critical-value diagnosis. Patients need language that separates association from blame: placental thrombi are not evidence that a parent caused the outcome, failed to take aspirin, or has an undiagnosed systemic clotting disorder.

Decision Point: The most useful future model will predict incremental risk beyond information already available from maternal disease, fetal growth, Dopplers, cord abnormalities, infarction, and inflammation. If IVT adds no independent, externally validated prognostic value, it should remain a contextual pathologic marker rather than a treatment target.

Audience Poll: Which advance is most likely to change practice first: automated IVT quantification, molecular determination of clot origin, antenatal placental MRI, or a multicenter recurrence cohort?

Case Study: Intervillous Thrombus and Adverse Pregnancy Outcome

A 32-year-old gravida 2 para 1 has a single umbilical artery identified at the 20-week anatomy examination. Cell-free DNA screening is low risk, and targeted anatomy shows no renal, cardiac, or other structural anomaly. Estimated fetal weight is at the 18th percentile at 30 weeks and the 8th percentile at 35 weeks. Amniotic fluid is normal, and umbilical-artery Doppler shows forward diastolic flow. At 36 weeks she develops gestational hypertension without severe features. Laboratory testing shows normal platelets, creatinine, and aminotransferases and no significant proteinuria.

The team increases fetal surveillance, reviews fetal movement precautions, and plans delivery based on gestational hypertension and FGR rather than on a presumed placental thrombus. Labor is induced at 37 weeks. A 2,420-g infant is delivered with Apgar scores of 8 and 9. The infant is vigorous, with no pallor or neurologic depression. Glucose and temperature are monitored because of SGA status; no respiratory support, empiric antibiotics, or transfusion is required.

Placental examination confirms a two-vessel cord and identifies two central IVTs measuring 1.4 and 0.7 cm, together involving less than 5% of the disc. Histology shows laminated fibrin and erythrocytes with peripheral villous compression. There is also a small peripheral infarct and stage 1 fetal inflammatory response consisting of focal umbilical phlebitis. There is no high-grade fetal vascular malperfusion, extensive perivillous fibrin, decidual arteriopathy, or retroplacental hematoma.

Decision Point: Did IVT cause the FGR? The correct answer is “not established.” The focal burden is limited, but IVT, infarction, SUA, and FIR reproduce the associations described in the recent database study. The growth trajectory and maternal hypertension indicate clinically meaningful placental risk, yet no single lesion independently explains the entire course.

For the newborn, IVT alone does not justify a complete blood count or fetomaternal-hemorrhage testing. Those tests would become appropriate for pallor, tachycardia, hypotension, hydrops, unexplained acidosis, or another anemia phenotype. Because the infant is well and intrapartum infection risk was low, the later finding of focal FIR is communicated and documented but does not automatically trigger antibiotics. Serial clinical assessment remains the decisive neonatal tool.

For the mother, postpartum blood-pressure surveillance and counseling about recurrence of hypertensive disease are more important than a thrombophilia panel. Testing for inherited thrombophilia or APS is not indicated from these pathology findings alone. A preconception review should verify whether additional personal, family, or obstetric history changes that assessment.

In a subsequent pregnancy, early dating, baseline blood pressure and renal assessment, a detailed anatomy examination, and third-trimester growth surveillance are reasonable. Low-dose aspirin should be prescribed if the complete preeclampsia-risk assessment meets guideline criteria—typically 81 mg daily beginning at 12–16 weeks in United States practice—not because IVT itself has a proven aspirin-responsive recurrence pathway. Surveillance and delivery timing should respond to recurrent hypertension, FGR, Doppler abnormalities, or fetal testing.

Teaching Point: The clinically useful conclusion is not “the placenta had clots, therefore anticoagulate.” It is: “This pregnancy demonstrated hypertensive and growth phenotypes with several associated placental findings; future care should target those reproducible risks while avoiding unproven IVT-specific treatment.”

Tonight on Shift

• [ ] Confirm that “intervillous thrombus” describes a circumscribed intervillous clot, not infarction, fetal-vessel thrombosis, or generic fibrin.
• [ ] Interpret IVT by number, size, location, placental burden, adjacent injury, and coexisting maternal, fetal, cord, and inflammatory lesions.
• [ ] Manage SUA, hypertension, FGR, abnormal Dopplers, suspected fetomaternal hemorrhage, and neonatal illness according to their own protocols.
• [ ] Do not order thrombophilia testing, aspirin, LMWH, neonatal antibiotics, or NICU admission for an isolated IVT alone.
• [ ] Communicate FIR and vascular findings without claiming that IVT caused infection, hypoxia, stillbirth, or fetal hemorrhage.
• [ ] Document the pathology in postpartum counseling and use the complete obstetric phenotype—not the word “thrombus”—to plan the next pregnancy.

Read this seminar as Markdown · All seminars · Lecture library · Question bank